CFJ Op-Ed: The Supreme Court Takes the Wrong Patent Case
- Jeffrey Depp
- Apr 8
- 2 min read
The Committee for Justice (CFJ) highlights a new op-ed examining the Supreme Court’s decision to hear Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.—a case that raises important questions about induced patent infringement, pharmaceutical innovation, and the future of U.S. drug policy.
In the op-ed, Jeffrey Depp argues that while Hikma presents a narrow legal issue—whether a generic manufacturer can be held liable for inducing infringement through conduct surrounding a “skinny label”—the Court’s decision to take the case reflects a broader policy trend. Specifically, it reflects an ongoing focus on reducing drug prices by accelerating generic entry, often without sufficient attention to the impact on innovation incentives.
The Bigger Issue Behind a Narrow Case
As explained in the op-ed, Hikma is not just a dispute over labeling and inducement doctrine. It sits within the broader framework of the Hatch-Waxman Act, which was designed to balance innovation and generic competition.
Over time, however, that framework has evolved into a complex and highly strategic system. As the article notes, Hatch-Waxman has produced a litigation-heavy environment in which both branded and generic firms adapt their behavior in response to regulatory incentives—often in ways that Congress did not anticipate.
The result is a system that is increasingly difficult to manage through additional layers of legal rules.
Innovation and the Limits of Legal Design
The op-ed also draws on insights from Austrian economics to highlight a deeper structural issue: the limits of government efforts to engineer outcomes in complex markets.
Pharmaceutical innovation is inherently uncertain and decentralized. As the article explains, many important medical advances—such as new uses for existing drugs—emerge only after years of additional research and investment.
Efforts to fine-tune this process through detailed legal frameworks, such as Hatch-Waxman or rigid inducement rules, risk producing unintended consequences. Rather than promoting competition, they can increase complexity, encourage strategic behavior, and ultimately weaken the incentives that drive innovation.
Why Patent Doctrine Still Matters
The op-ed emphasizes that the Court’s focus in Hikma comes at the expense of more pressing issues in patent law.
For years, litigants have sought clarification of the Court’s patent subject matter eligibility (SME) jurisprudence under § 101—particularly as it applies to diagnostic technologies. The current uncertainty in this area has significant implications for investment in cutting-edge therapies, including those that rely on companion diagnostics.
Clarifying SME doctrine, the article argues, would do far more to support long-term pharmaceutical innovation—and competition—than further refining rules governing generic entry under Hatch-Waxman.
A Missed Opportunity
Ultimately, the op-ed concludes that the Supreme Court’s decision to take Hikma reflects a misplaced priority. By focusing on a narrow dispute aligned with short-term pricing concerns, the Court risks overlooking broader structural issues that affect innovation across the entire economy.
If the goal is to promote meaningful competition and improve patient outcomes, the article argues, policymakers should focus on strengthening and stabilizing patent rights—rather than continuing to layer additional complexity onto an already intricate system.
